Safety analysis
Mild adhesion of the nasal cavity occurred in 3 patients in the control
group, 3 patients in the rh-bFGF nasal-spray group and 2 patients in the
rh-bFGF nasal-drop group. No significant difference in the adverse event
rate was found among the three groups (P=0.86). No extensive adhesion
and no major side effects were reported during the trial.